帯状疱疹ワクチン市場、2026年～2032年：製品タイプ、ワクチンタイプ、流通チャネル、年齢層、地域別

帯状疱疹ワクチン市場の評価-2026年～2032年

慢性疾患の有病率の上昇と高齢化が帯状疱疹ワクチン市場の需要を牽引しています。さらに、帯状疱疹ワクチンは、水痘帯状疱疹ウイルスによって引き起こされる帯状疱疹の予防に役立つワクチン接種の重要性に関する意識の高まりが、2024年に評価された16億2,000万米ドルの売上高を超え、2032年までに34億7,000万米ドルに達することが予測され、市場を活性化すると考えられます。

また、ワクチン技術の開発と、より効果的な新ワクチンの開発も、帯状疱疹ワクチン市場の成長を促進すると予想されます。先進国におけるヘルスケア政策の実施が増加していることから、2026年から2032年にかけてのCAGRは約10%で市場の成長を可能にしています。

帯状疱疹ワクチン市場定義/概要

帯状疱疹ワクチンは、一般に帯状疱疹ワクチンと呼ばれ、水痘の原因でもある水痘帯状疱疹ウイルスの再活性化によって引き起こされる帯状疱疹に対する重要な予防手段です。このワクチンには弱毒化されたウイルスが含まれており、免疫系を刺激して抗体を産生させ、帯状疱疹の予防や重症度の軽減を可能にします。このワクチンの主な用途は、加齢に伴う免疫力の低下によりリスクが高まる50歳以上の人の帯状疱疹を予防することにあります。さらに、このワクチンは、慢性疼痛や神経学的問題など、帯状疱疹に伴う合併症の軽減にも役立ちます。

現在、利用可能な帯状疱疹ワクチンには、主にShingrixとZostavaxの2種類があり、今後の調査では、より幅広い用途でさらに効果的な選択肢が模索されています。帯状疱疹関連疾患の世界の負担を軽減するために、特に低・中所得国において、世界のアクセスを強化する取り組みが行われています。

世界の帯状疱疹患者の増加は帯状疱疹ワクチン市場の成長を促進するか？

帯状疱疹の有病率は、高齢化、免疫力の低下、がんやHIVのような慢性疾患の有病率の増加などの要因により世界的に上昇しており、帯状疱疹ワクチン市場の成長を促進します。

その結果、帯状疱疹を予防するためのワクチン接種の重要性を認識する人が増えるため、帯状疱疹ワクチンの需要は今後数年で増加する可能性が高いです。これは帯状疱疹ワクチン市場の成長にとって大きな機会となります。例えば、2023年4月25日、GSKは帯状疱疹ワクチン（帯状疱疹）を発売しました。GSK社によると、このワクチンの有効性は90%で、帯状疱疹に対して少なくとも10年間の予防効果があるといいます。

帯状疱疹を予防するためのワクチン接種の重要性に対する人々の意識の高まりが、帯状疱疹ワクチン市場の需要を牽引しています。高齢者は帯状疱疹にかかりやすいため、世界の高齢化も市場の成長に寄与しています。例えば、インド人を対象とした血清有病率調査によると、40歳までに参加者の90％以上が体内にこのウイルスを保有しており、そのため帯状疱疹にかかりやすいことが示されています。帯状疱疹と帯状疱疹後神経痛の予防のために、シングリックスワクチンは50歳以上の成人に承認されています。

さらに、ワクチン技術の進歩や、より効果的な新ワクチンの開発が市場の成長を後押しすると予想されます。これら全ての要因から、帯状疱疹ワクチン市場は今後数年間で安定した成長を遂げるものと思われます。

帯状疱疹ワクチンの高コストは帯状疱疹ワクチン市場の成長を妨げるか？

帯状疱疹ワクチンの高コスト化は、特に低所得国の多くの人々にとって大きな障壁となり、帯状疱疹ワクチン市場の成長を妨げる可能性があります。このコストの障壁は、研究開発の複雑さ、製造工程、流通物流、効果的な免疫を確保するための複数回接種の必要性など、様々な要因に起因しています。

さらに、ヘルスケアプロバイダーや医療機関は、帯状疱疹ワクチンのような高コストのワクチンを購入する際、特に償還率が不十分な環境では財政的な制約に直面する可能性があります。このため、ワクチン接種へのアクセスがさらに制限され、全体的な需要が減少し、市場の成長が制約される可能性があります。

厳格な規制に対する認識の高まりは、帯状疱疹ワクチン市場の成長にとって確かに課題となりうる。ワクチンの承認プロセスには時間とコストがかかるため、新しいワクチンの上市が遅れ、入手が制限される可能性があります。さらに、安全性と有効性に関する規制要件が厳しいこともあり、新規メーカーの市場参入を困難にする可能性があります。

さらに、ワクチンによる発疹の増加が帯状疱疹ワクチン市場の成長を阻害する可能性もあります。ワクチン接種後に発疹などの副反応が発生すると、ワクチンに対する信頼が低下し、需要が減少する可能性があります。これは最終的に市場の成長に影響を与える可能性があります。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査スケジュール
• 前提条件
• 限界

第2章 調査手法

• データマイニング
• 2次調査
• 1次調査
• 専門家の助言
• クオリティチェック
• 最終レビュー
• データの三角測量
• ボトムアップアプローチ
• トップダウン・アプローチ
• 調査の流れ
• オピニオン

第3章 エグゼクティブサマリー

• 帯状疱疹ワクチンの世界市場概要
• 帯状疱疹ワクチンの世界市場推定・予測、2024年～2030年
• 帯状疱疹ワクチンの世界市場価値の推定・予測、2024年～2030年
• 帯状疱疹ワクチンの世界エコロジーマッピング（2022年シェア）
• 競合分析：ファネルダイアグラム
• 帯状疱疹ワクチンの世界市場絶対的収益機会
• 帯状疱疹ワクチンの世界市場の魅力分析、地域別
• 帯状疱疹ワクチンの世界市場の魅力分析：製品タイプ別
• 帯状疱疹ワクチンの世界市場の魅力分析：ワクチンタイプ別
• 帯状疱疹ワクチンの世界市場の魅力度分析：年齢層別
• 帯状疱疹ワクチンの世界市場の魅力度分析：販売チャネル別
• 帯状疱疹ワクチンの世界市場：製品タイプ別
• 帯状疱疹ワクチンの世界市場：ワクチンタイプ別
• 帯状疱疹ワクチンの世界市場：年齢層別
• 帯状疱疹ワクチンの世界市場：販売チャネル別
• 今後の市場機会

第4章 市場展望

• 帯状疱疹ワクチンの世界市場の変遷
• 帯状疱疹ワクチンの世界市場展望
• 市場促進要因
  • 帯状疱疹の有病率の増加
  • 帯状疱疹に対する意識の高まり
• 市場抑制要因
  • ワクチンの高コスト
• 市場動向
  • 人口の高齢化
• 市場機会
  • ワクチン技術の開発
• ポーターのファイブフォース分析
  • 新規参入業者の脅威
  • 代替品の脅威
  • 供給企業の交渉力
  • 買い手の交渉力
  • 競争企業間の敵対関係の強さ
• マクロ経済分析
• バリューチェーン分析
• 価格分析
• 規制
  • サウジアラビア食品医薬品局（SFDA）
• 製品ライフライン

第5章 製品タイプ別市場

• 概要
• 帯状疱疹ワクチンの世界市場：製品タイプ別ベーシス・ポイント・シェア（bps）分析
• ゾスタバックス
• シングリックス
• スカイゾスター

第6章 ワクチンタイプ別市場

• 概要
• 帯状疱疹ワクチンの世界市場：ワクチンタイプ別ベーシス・ポイント・シェア（bps）分析
• 弱毒生ワクチン
• 組み換えワクチン

第7章 市場：流通チャネル別

• 概要
• 帯状疱疹ワクチンの世界市場：流通チャネル別ベーシス・ポイント・シェア（bps）分析
• 民間
• 公的

第8章 年齢層別市場

• 概要
• 帯状疱疹ワクチンの世界市場：年齢層別ベーシスポイントシェア（bps）分析
• 50歳以上65歳未満
• 65歳以上
• 18歳以上50歳未満

第9章 地域別市場

• 概要
  • インド
  • 台湾
  • タイ
  • サウジアラビア
  • アラブ首長国連邦
  • トルコ
  • ブラジル
  • メキシコ
  • アルゼンチン

第10章 競合情勢

• 概要
• 競合シナリオ
• 市場ランキング分析
• 地域別フットプリント
• 企業の産業別フットプリント
• エースマトリックス
  • アクティブ
  • カッティング・エッジ
  • エマージング
  • イノベーター

第11章 企業プロファイル

• GLAXOSMITHKLINE PLC.
• MERCK & CO., INC.
• SK BIOSCIENCES（SK CHEMICALS）
• GENEONE LIFE SCIENCE
• PFIZER
• CANSINO BIOLOGICS INC.
• VACCITECH
• INOVIO PHARMACEUTICALS, INC.
• CUREVO INC.

LIST OF TABLES

• TABLE1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES
• TABLE 2 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
• TABLE 3 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 4 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
• TABLE 5 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 6 GLOBAL ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
• TABLE 7 GLOBAL ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
• TABLE 8 GLOBAL ZOSTER VACCINE MARKET, BY GEOGRAPHY, 2021-2030 (USD MILLION)
• TABLE 9 GLOBAL ZOSTER VACCINE MARKET, BY GEOGRAPHY, 2021-2030 (THOUSAND DOSES)
• TABLE10 INDIA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
• TABLE11 INDIA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE12 INDIA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
• TABLE13 INDIA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE14 INDIA ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
• TABLE15 INDIA ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
• TABLE16 TAIWAN ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
• TABLE17 TAIWAN ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE18 TAIWAN ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
• TABLE19 TAIWAN ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 20 TAIWAN ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
• TABLE 21 TAIWAN ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
• TABLE 22 THAILAND ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
• TABLE 23 THAILAND ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 24 THAILAND ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
• TABLE 25 THAILAND ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 26 THAILAND ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
• TABLE 27 THAILAND ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
• TABLE 28 SAUDI ARABIA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
• TABLE 29 SAUDI ARABIA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 30 SAUDI ARABIA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
• TABLE 31 SAUDI ARABIA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 32 SAUDI ARABIA ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
• TABLE 33 SAUDI ARABIA ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
• TABLE 34 UAE ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
• TABLE 35 UAE ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 36 UAE ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
• TABLE 37 UAE ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 38 UAE ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
• TABLE 39 UAE ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
• TABLE 40 TURKEY ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
• TABLE 41 TURKEY ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 42 TURKEY ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
• TABLE 43 TURKEY ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 44 TURKEY ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
• TABLE 45 TURKEY ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
• TABLE 46 BRAZIL ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
• TABLE 47 BRAZIL ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 48 BRAZIL ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
• TABLE 49 BRAZIL ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 50 BRAZIL ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
• TABLE 51 BRAZIL ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
• TABLE 52 MEXICO ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
• TABLE 53 MEXICO ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 54 MEXICO ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
• TABLE 55 MEXICO ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 56 MEXICO ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
• TABLE 57 MEXICO ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
• TABLE 58 ARGENTINA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
• TABLE 59 ARGENTINA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 60 ARGENTINA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
• TABLE 61 ARGENTINA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
• TABLE 62 ARGENTINA ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
• TABLE 63 ARGENTINA ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
• TABLE 64 COMPANY REGIONAL FOOTPRINT
• TABLE 65 COMPANY INDUSTRY FOOTPRINT
• TABLE 66 GLAXOSMITHKLINE PLC.: PRODUCT BENCHMARKING
• TABLE 67 GLAXOSMITHKLINE PLC.: KEY DEVELOPMENTS
• TABLE 68 GLAXOSMITHKLINE PLC.: WINNING IMPERATIVES
• TABLE 69 MERCK & CO., INC.: PRODUCT BENCHMARKING
• TABLE 70 MERCK & CO., INC.: WINNING IMPERATIVES
• TABLE 71 SK BIOSCIENCES (SK CHEMICALS): PRODUCT BENCHMARKING
• TABLE 72 SK BIOSCIENCES (SK CHEMICALS): WINNING IMPERATIVES
• TABLE 73 GENEONE LIFE SCIENCE: PRODUCT BENCHMARKING
• TABLE 74 PFIZER: PRODUCT BENCHMARKING
• TABLE 75 PFIZER: KEY DEVELOPMENTS
• TABLE 76 CANSINO BIOLOGICS INC.: PRODUCT BENCHMARKING
• TABLE 77 VACCITECH: PRODUCT BENCHMARKING
• TABLE 78 VACCITECH: KEY DEVELOPMENTS
• TABLE 79 CUREVO INC.: PRODUCT BENCHMARKING

LIST OF FIGURES

• FIGURE1 GLOBAL ZOSTER VACCINE MARKET SEGMENTATION
• FIGURE 2 RESEARCH TIMELINES
• FIGURE 3 DATA TRIANGULATION
• FIGURE 4 MARKET RESEARCH FLOW
• FIGURE 5 THOUGHT LEADERSHIP OPINION
• FIGURE 6 SUMMARY
• FIGURE 7 GLOBAL ZOSTER VACCINE MARKET ESTIMATES AND FORECAST (USD MILLION), 2024-2030
• FIGURE 8 GLOBAL ZOSTER VACCINE MARKET VALUE (USD MILLION) AND FORECAST, 2024-2030
• FIGURE 9 GLOBAL ZOSTER VACCINE ECOLOGY MAPPING (% SHARE IN 2022)
• FIGURE10 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• FIGURE11 GLOBAL ZOSTER VACCINE MARKET ABSOLUTE MARKET OPPORTUNITY
• FIGURE12 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• FIGURE13 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT TYPE
• FIGURE14 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY VACCINE TYPE
• FIGURE15 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY AGE GROUP
• FIGURE16 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY SALES CHANNEL
• FIGURE17 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE (USD MILLION)
• FIGURE18 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE (USD MILLION)
• FIGURE19 GLOBAL ZOSTER VACCINE MARKET, BY AGE GROUP (USD MILLION)
• FIGURE 20 GLOBAL ZOSTER VACCINE MARKET, BY SALES CHANNEL (USD MILLION)
• FIGURE 21 FUTURE MARKET OPPORTUNITIES
• FIGURE 22 GLOBAL ZOSTER VACCINE MARKET OUTLOOK
• FIGURE 23 MARKET DRIVERS IMPACT ANALYSIS
• FIGURE 24 RESTRAINTS IMPACT ANALYSIS
• FIGURE 25 KEY TRENDS
• FIGURE 26 PORTER'S FIVE FORCES ANALYSIS
• FIGURE 27 ZOSTER VACCINES MARKET PRICES BY REGION UNIT/DOSE)
• FIGURE 28 PRODUCT LIFELINE: ELECTRICAL STEEL SHEET MARKET
• FIGURE 29 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE
• FIGURE 30 GLOBAL ZOSTER VACCINE MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT TYPE
• FIGURE 31 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE
• FIGURE 32 GLOBAL ZOSTER VACCINE MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY VACCINE TYPE
• FIGURE 33 GLOBAL ZOSTER VACCINE MARKET, BY SALES CHANNEL
• FIGURE 34 GLOBAL ZOSTER VACCINE MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY SALES CHANNEL
• FIGURE 35 GLOBAL ZOSTER VACCINE MARKET, BY AGE GROUP
• FIGURE 36 GLOBAL ZOSTER VACCINE MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY AGE GROUP
• FIGURE 37 GLOBAL ZOSTER VACCINE MARKET, BY GEOGRAPHY, 2021-2030 (USD MILLION)
• FIGURE 38 GLOBAL ZOSTER VACCINE MARKET, BY GEOGRAPHY, 2021-2030 (THOUSAND DOSES)
• FIGURE 39 INDIA MARKET SNAPSHOT
• FIGURE 40 TAIWAN MARKET SNAPSHOT
• FIGURE 41 THAILAND MARKET SNAPSHOT
• FIGURE 42 SAUDI ARABIA MARKET SNAPSHOT
• FIGURE 43 UAE MARKET SNAPSHOT
• FIGURE 44 HERPES ZOSTER INCIDENCE PER ONE MILLION POPULATION, BY AGE, 2018 & 2019
• FIGURE 45 TURKEY MARKET SNAPSHOT
• FIGURE 46 NUMBER OF HERPS ZOSTER DIAGNOSES REPORTED IN MARCH -AUGUST (2018-2020)
• FIGURE 47 BRAZIL MARKET SNAPSHOT
• FIGURE 48 MEXICO MARKET SNAPSHOT
• FIGURE 49 ARGENTINA MARKET SNAPSHOT
• FIGURE 50 KEY STRATEGIC DEVELOPMENTS
• FIGURE 51 COMPANY MARKET RANKING ANALYSIS
• FIGURE 52 ACE MATRIC
• FIGURE 53 GLAXOSMITHKLINE PLC.: COMPANY INSIGHT
• FIGURE 54 GLAXOSMITHKLINE PLC.: BREAKDOWN
• FIGURE 55 GLAXOSMITHKLINE PLC.: SWOT ANALYSIS
• FIGURE 56 MERCK & CO., INC.: COMPANY INSIGHT
• FIGURE 57 MERCK & CO., INC.: BREAKDOWN
• FIGURE 58 MERCK & CO., INC.: SWOT ANALYSIS
• FIGURE 59 SK BIOSCIENCES (SK CHEMICALS): COMPANY INSIGHT
• FIGURE 60 SK BIOSCIENCES (SK CHEMICALS): SWOT ANALYSIS
• FIGURE 61 GENEONEE LIFE SCIENCE: COMPANY INSIGHT
• FIGURE 62 PFIZER: COMPANY INSIGHT
• FIGURE 63 PFIZER: BREAKDOWN
• FIGURE 64 CANSINO BIOLOGICS INC.: COMPANY INSIGHT
• FIGURE 65 CANSINO BIOLOGICS INC.: BREAKDOWN
• FIGURE 66 VACCITECH: COMPANY INSIGHT
• FIGURE 67 INOVIO PHARMACEUTICALS, INC.: COMPANY INSIGHT
• FIGURE 68 INOVIO PHARMACEUTICALS, INC.: BREAKDOWN
• FIGURE 69 CUREVO INC.: COMPANY INSIGHT

Zoster Vaccine Market Valuation - 2026-2032

The rising prevalence of chronic diseases and the aging population are driving the demand for zoster vaccine market. Additionally, the zoster vaccine can be attributed to the increasing awareness regarding the importance of vaccination in helping to prevent shingles caused by the varicella-zoster virus is anticipated to fuel the market to surpass revenue of USD 1.62 Billion valued in 2024 and reach USD 3.47 Billion by 2032.

Also, growing advancements in vaccine technology and the development of new and more effective vaccines are also expected to propel the growth of the zoster vaccine market. The increasing implementation of healthcare policies in developed nations is enabling the market grow at a CAGR of about 10% from 2026 to 2032.

Zoster Vaccine Market: Definition/ Overview

The zoster vaccine, commonly referred to as the shingles vaccine, is a crucial preventive measure against herpes zoster, an ailment triggered by the reactivation of the varicella-zoster virus, which also causes chickenpox. This vaccine contains a weakened form of the virus, stimulating the immune system to produce antibodies that can prevent or mitigate the severity of shingles. Its primary application lies in preventing shingles in individuals aged 50 and older, who are at an increased risk due to age-related decline in immunity. Additionally, the vaccine helps in reducing complications associated with shingles, such as chronic pain and neurological issues.

Currently, there are two main types of zoster vaccines available that are Shingrix and Zostavax and future research is exploring even more effective options with broader applications. The Protection and require fewer doses, potential expansion of recommendations to include younger age groups or those with specific medical conditions, exploration of combination vaccines for simplified immunization schedules, and efforts to enhance global access, particularly in low- and middle-income countries, to alleviate the burden of shingles-related illness on a global scale.

Will Increasing Cases of Herpes Zoster Worldwide Drive the Growth of the Zoster Vaccine Market?

The prevalence of herpes zoster disease is rising globally due to factors such as the aging population, weakened immune systems, and increased prevalence of chronic diseases such as cancer and HIV will drive the growth of the zoster vaccine market

As a result, the demand for zoster vaccine is likely to increase in the coming years as more people become aware of the importance of vaccination to prevent shingles. This presents a significant opportunity for the growth of the zoster vaccine market. For instance, on 25 April 2023, GSK launched the shingles vaccine, (herpes zoster). GSK said the vaccine had 90% efficacy and provided at least 10 years of protection against herpes zoster.

The growing awareness among people about the importance of vaccination to prevent shingles is driving the demand for the zoster vaccine market. The aging population worldwide is also contributing to the growth of the market as older adults are more susceptible to shingles. For instance, according seroprevalence study in Indian subjects showed that by the age of 40 years, more than 90% of the participants had this virus in their bodies and were therefore vulnerable to shingles. For the prevention of shingles and post-herpetic neuralgia, Shingrix vaccine has been approved for adults above 50 years.

Furthermore, advancements in vaccine technology and the development of new and more effective vaccines are expected to boost the growth of the market. All these factors suggest that the zoster vaccine market is poised for steady growth in the coming years.

Will The High Cost of Zoster Vaccine Hamper the Growth of the Zoster Vaccine Market?

Increasing the high cost of the zoster vaccine can be a significant barrier for many people, especially in low-income countries, and it could potentially hamper the growth of the zoster vaccine market. This cost barrier stems from various factors, including the complexities of research and development, manufacturing processes, distribution logistics, and the necessity for multiple doses to ensure effective immunity.

Additionally, healthcare providers and institutions may face financial constraints in purchasing high-cost vaccines like the zoster vaccine, particularly in settings where reimbursement rates are inadequate. This can further limit access to vaccination and reduce overall demand, constraining market growth.

Growing awareness of stringent regulations can indeed pose a challenge to the growth of the zoster vaccine market. The regulatory approval process for vaccines can be lengthy and costly, which can delay the launch of new vaccines and limit their availability. Additionally, regulatory requirements for safety and efficacy can be strict, which can make it difficult for new manufacturers to enter the market.

Furthermore, the increasing occurrence of vaccine rashes can indeed hinder the growth of the zoster vaccine market. When people experience rashes or other adverse reactions after receiving a vaccine, it can lead to a decrease in confidence in the vaccine and reduce demand for it. This can ultimately impact the growth of the market.

Category-Wise Acumens

Will the Rising Utilization of the Shingrix Vaccine Drive the Zoster Vaccine Market?

The rising use of the Shingrix vaccine is expected to drive the zoster vaccine market. Shingrix is a highly effective vaccine for preventing zoster, and it has been shown to provide longer-lasting protection than other available vaccines. This vaccine provides a high level of immunity for at least 7 years after vaccination, as more people become aware of the benefits of Shingrix the demand for the vaccine is expected to increase, which will help to drive growth in the zoster vaccine market.

Additionally, during the forecast period, there will be a rise in demand for these vaccinations due to increasing awareness of the disease's effects and the growing number of countries that have approved Shingrix for use as a vaccine. For instance, GSK announced the shingles vaccine Shingrix in India. This vaccine is recommended for people aged 50 years and above to protect against shingles.

Increasing awareness of the importance of shingles vaccination will drive the zoster vaccine market Companies may invest in marketing efforts to differentiate their products and highlight their efficacy and safety profiles. Additionally, the drive for innovation may lead to the development of new vaccine formulations or delivery methods to better meet the needs of consumers.

The surge in demand for shingles vaccines propels market expansion, prompting vaccine manufacturers to bolster production capacities to satisfy healthcare providers and consumer requirements. This heightened production not only addresses immediate demand but also fosters increased investment in research and development. As revenue streams grow, manufacturers allocate more resources to R&D endeavors, aiming to enhance vaccine efficacy, safety, and accessibility

Increasing demand for technological developments in vaccine formulation, delivery, and production are improving the accessibility, safety, and efficacy of vaccinations. This accelerates the market's growth for zoster vaccines, providing better preventive treatments and enhanced public health results.

Will Increasing Demand for Recombinant Vaccine will Boost the Zoster Vaccine Market?

Recombinant vaccines are produced using genetic engineering techniques, which allows for more precise targeting of the virus or bacteria being targeted. This technology has been used to develop new vaccines, including the Shingrix vaccine for shingles. The growing use of recombinant vaccines offers several advantages over traditional vaccines, including improved safety, efficacy, and ease of production. As a result, they are becoming increasingly popular among healthcare providers and patients. This vaccine contains purified parts of pathogen that are antigenic, or necessary to elicit a protective immune response.

In addition to the benefits of recombinant vaccines, other factors such as the aging population, increasing healthcare expenditure, and rising awareness regarding the importance of preventive healthcare are expected to contribute to the growth of the zoster vaccine market. Aging comes with several health problems such as a weak immune system, which make the old population susceptible to infections like shingles. The increasing geriatric population globally estimated at 3 to 5 cases per 1000 individuals annually is contributing to the growth of the zoster vaccine market and is expected to continue its growth throughout the forecast period.

Country/Region-wise

How the Increasing Prevalence of Chickenpox in North America will Drive the Zoster Vaccine Market?

The rising prevalence of chickenpox in North America boost the zoster vaccine market. Chickenpox and shingles are caused by the same virus, known as the varicella-zoster virus. While chickenpox is a common childhood illness, the virus can remain dormant in the body and reactivate later in life as shingles. Additionally, recommendations for shingles vaccine may be part of the public health response to chickenpox outbreaks, especially for those who are more susceptible due to age or underlying medical issues. For Instance, on 7 September 2022, 21,060 cases of chickenpox were recorded by Mexican health authorities (11,057 males and 10,003 women). This is a significantly higher number than the 8,897 cases reported in 2021, a 137% rise. The likelihood of developing shingles is increased by the high prevalence of chickenpox.

The rising healthcare expenditure in North America has led to a surge in demand for the Zoster vaccine, thereby driving the growth of the market. This vaccine is highly effective in preventing shingles, which is a painful skin rash caused by the reactivation of the varicella-zoster virus.

Rising awareness regarding preventive healthcare will drive the zoster vaccine market. Public health campaigns and a growing focus on preventative measures are making people more aware of the importance of proactive healthcare. This shift in perspective is leading to a greater willingness to get vaccinated against diseases like shingles. People are becoming more informed about the potential complications of shingles, such as PHN, and understand the value of vaccination in preventing this debilitating condition. This growing awareness will likely lead to a significant increase in the demand for zoster vaccines in the coming years.

Will Growing Awareness of Government Vaccine Programs in Asia Pacific Drive the Zoster Vaccine Market?

Growing awareness of government vaccine programs in the Asia-Pacific region is expected to drive the demand for zoster vaccines and contribute to the growth of the market. Many governments in the region have launched vaccination programs to prevent various diseases, including shingles. These programs aim to increase awareness about vaccination and make vaccines more accessible to the population, especially older adults who are more susceptible to shingles.

For example, in Japan, the government has included the zoster vaccine in its national vaccination program for older adults, which covers the cost of the vaccine for eligible individuals. Additionally, in India, the government has launched various vaccination programs to prevent diseases such as hepatitis, influenza, and pneumococcal disease, which are also expected to increase awareness about the importance of vaccination and drive the demand for zoster vaccine.

Changing lifestyles in Asia-Pacific are expected to drive the zoster vaccine market. As people in the region become more health-conscious and adopt healthier lifestyles, the risk of developing shingles may decrease. However, the demand for zoster vaccine is still expected to increase as people become more aware of the importance of vaccination and take preventive measures to protect themselves against the disease.

Furthermore, government initiatives are expected to boost the growth of the market and encourage more manufacturers to invest in the development of new and more effective vaccines for shingles.

Competitive Landscape

The zoster vaccine market, while experiencing promising growth, is a concentrated landscape with a few key players vying for dominance. The zoster vaccine market is dynamic and competitive and will benefit public health. It can lead to the development of more effective, accessible, and affordable vaccines, offering broader protection against shingles and its debilitating complications. The interplay between established players, innovative newcomers, and regulatory bodies will define the future of the zoster vaccine market.

Some of the prominent players operating in the zoster vaccine market include:

• GSK plc
• Merck & Co., Inc.
• Curevo Inc
• Geneone Life Science
• SK bioscience

Latest Developments

• In February 2023, Pfizer Inc. and BioNTech SE launched a phase 1/2 trial to investigate the safety, tolerability, and immunogenicity of their mRNA vaccine candidates against varicella-zoster virus (VZV), which causes shingles, a severe condition referred to as herpes zoster, or HZ
• In April 2023, GSK launched an anti-shingles vaccine in India. The vaccine is used to prevent herpes zoster and neuralgia in adults aged 50 years old
• In February 2023, Jiangsu Recbio Technology Co., Ltd completed the first batch of subject enrollment for its adjuvant recombinant shingles vaccine, REC610.

Zoster Vaccine Market, By Category

• Product Type
• Zostavax
• Shingrix
• SKYZoster
• Vaccine Type:
• Recombinant Vaccine
• Live Attenuated Vaccine
• Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Age Group:
• Above 50 to 65 Age
• Above 65 Age
• Above 18 to 50 Age
• Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 THOUGHT LEADERSHIP OPINION

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL ZOSTER VACCINE MARKET OVERVIEW
• 3.2 GLOBAL ZOSTER VACCINE MARKET ESTIMATES AND FORECAST (USD MILLION), 2024-2030
• 3.3 GLOBAL ZOSTER VACCINE MARKET VALUE (USD MILLION) ESTIMATES AND FORECAST, 2024-2030
• 3.4 GLOBAL ZOSTER VACCINE ECOLOGY MAPPING (% SHARE IN 2022)
• 3.5 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.6 GLOBAL ZOSTER VACCINE MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.7 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.8 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT TYPE
• 3.9 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY VACCINE TYPE
• 3.10 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY AGE GROUP
• 3.11 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY SALES CHANNEL
• 3.12 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE (USD MILLION)
• 3.13 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE (USD MILLION)
• 3.14 GLOBAL ZOSTER VACCINE MARKET, BY AGE GROUP (USD MILLION)
• 3.15 GLOBAL ZOSTER VACCINE MARKET, BY SALES CHANNEL (USD MILLION)
• 3.16 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL ZOSTER VACCINE MARKET EVOLUTION
• 4.2 GLOBAL ZOSTER VACCINE MARKET OUTLOOK
• 4.3 MARKET DRIVERS
  • 4.3.1 INCREASING PREVALENCE OF HERPES ZOSTER
  • 4.3.2 GROWING AWARENESS ABOUT HERPES ZOSTER
• 4.4 MARKET RESTRAINTS
  • 4.4.1 HIGH COST OF VACCINES
• 4.5 MARKET TRENDS
  • 4.5.1 AGEING POPULATION
• 4.6 MARKET OPPORTUNITY
  • 4.6.1 DEVELOPMENTS IN VACCINE TECHNOLOGY
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 THREAT OF SUBSTITUTES
  • 4.7.3 BARGAINING POWER OF SUPPLIERS
  • 4.7.4 BARGAINING POWER OF BUYERS
  • 4.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 4.8 MACROECONOMIC ANALYSIS
• 4.9 VALUE CHAIN ANALYSIS
• 4.10 PRICING ANALYSIS
• 4.11 REGULATIONS
  • 4.11.1 SAUDI FOOD AND DRUG AUTHORITY (SFDA)
• 4.12 PRODUCT LIFELINE

5 MARKET, BY PRODUCT TYPE

• 5.1 OVERVIEW
• 5.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT TYPE
• 5.3 ZOSTAVAX
• 5.4 SHINGRIX
• 5.5 SKYZOSTER

6 MARKET, BY VACCINE TYPE

• 6.1 OVERVIEW
• 6.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY VACCINE TYPE
• 6.1 LIVE ATTENUATED VACCINE
• 6.2 RECOMBINANT VACCINE

7 MARKET, BY SALES CHANNEL

• 7.1 OVERVIEW
• 7.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY SALES CHANNEL
• 7.3 PRIVATE
• 7.4 PUBLIC

8 MARKET, BY AGE GROUP

• 8.1 OVERVIEW
• 8.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY AGE GROUP
• 8.3 ABOVE 50 TO 65 AGE
• 8.4 ABOVE 65 AGE
• 8.5 ABOVE18 TO 50 AGE

9 MARKET, BY GEOGRAPHY

• 9.1 OVERVIEW
  • 9.1.1 INDIA
  • 9.1.2 TAIWAN
  • 9.1.3 THAILAND
  • 9.1.4 SAUDI ARABIA
  • 9.1.5 UAE
  • 9.1.6 TURKEY
  • 9.1.7 BRAZIL
  • 9.1.8 MEXICO
  • 9.1.9 ARGENTINA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE SCENARIO
• 10.3 COMPANY MARKET RANKING ANALYSIS
• 10.4 COMPANY REGIONAL FOOTPRINT
• 10.5 COMPANY INDUSTRY FOOTPRINT
• 10.6 ACE MATRIX
  • 10.6.1 ACTIVE
  • 10.6.2 CUTTING EDGE
  • 10.6.3 EMERGING
  • 10.6.4 INNOVATORS

11 COMPANY PROFILES

• 11.1 GLAXOSMITHKLINE PLC.
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 COMPANY INSIGHTS
  • 11.1.3 SEGMENT BREAKDOWN
  • 11.1.4 PRODUCT BENCHMARKING
  • 11.1.5 KEY DEVELOPMENTS
  • 11.1.6 SWOT ANALYSIS
  • 11.1.7 WINNING IMPERATIVES
  • 11.1.8 CURRENT FOCUS & STRATEGIES
  • 11.1.9 THREAT FROM COMPETITION
• 11.2 MERCK & CO., INC.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 COMPANY INSIGHTS
  • 11.2.3 SEGMENT BREAKDOWN
  • 11.2.4 PRODUCT BENCHMARKING
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 WINNING IMPERATIVES
  • 11.2.7 CURRENT FOCUS & STRATEGIES
  • 11.2.8 THREAT FROM COMPETITION
• 11.3 SK BIOSCIENCES (SK CHEMICALS)
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 COMPANY INSIGHTS
  • 11.3.3 PRODUCT BENCHMARKING
  • 11.3.4 SWOT ANALYSIS
  • 11.3.5 WINNING IMPERATIVES
  • 11.3.6 CURRENT FOCUS & STRATEGIES
  • 11.3.7 THREAT FROM COMPETITION
• 11.4 GENEONE LIFE SCIENCE
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 COMPANY INSIGHTS
  • 11.4.3 PRODUCT BENCHMARKING
• 11.5 PFIZER
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 COMPANY INSIGHTS
  • 11.5.3 SEGMENT BREAKDOWN
  • 11.5.4 PRODUCT BENCHMARKING
  • 11.5.5 KEY DEVELOPMENTS
• 11.6 CANSINO BIOLOGICS INC.
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 COMPANY INSIGHTS
  • 11.6.3 SEGMENT BREAKDOWN
  • 11.6.4 PRODUCT BENCHMARKING
• 11.7 VACCITECH
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 COMPANY INSIGHTS
  • 11.7.3 PRODUCT BENCHMARKING
  • 11.7.4 KEY DEVELOPMENTS
• 11.8 INOVIO PHARMACEUTICALS, INC.
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 COMPANY INSIGHTS
  • 11.8.3 SEGMENT BREAKDOWN
• 11.9 CUREVO INC.
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 COMPANY INSIGHTS
  • 11.9.3 PRODUCT BENCHMARKING